KRX extends Gene One Life Science listing review committee deadline to Oct. 30, trade suspension continues

• KRX extended the deadline to convene a listing review committee for Gene One Life Science to Oct. 30, 2026.
• The review follows a substantive listing-eligibility examination triggered by a July 16, 2026 disclosure of a major management matter.
• Trading in the company’s shares will remain suspended until a decision on continued listing eligibility is reached.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260928800707), on September 28, 2026, and is solely responsible for the information contained therein.